Enliven Therapeutics, Inc.
ELVN
NASDAQ·Healthcare·Biotechnology·Mkt cap $4.2B
$59.32
▼ -0.55%
P/E
-36.17
Mkt Cap
$4.2B
52-Wk Range
$14.79–$62.32
52-Week Range
$14.79 - $62.32
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 196.3% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
3 reasons
- Focused pipeline targeting high-prevalence cancers with validated genetic drivers
- Small molecule platform enabling rapid optimization and oral bioavailability
- Strategic focus on kinase inhibition with potential for differentiated efficacy and safety profiles
Bear Case
1 risk
- Low volatility (beta 0.2).
Growth
Stable outlook
Advancement of ELVN-001 and ELVN-002 through clinical development stages
Value
Deep value opportunity - significant discount to Biotech & Therapeutics peers
Momentum
Hot
+76.4% over 3m
Quality
Loss-making
Solid business
Dividend
None
No dividend
Smart-money signal
Who's buying ELVN right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Recent earnings results
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Nov 11, 2026
AUG 5, 2026
Reported EPS of -$0.49 vs -$0.39 consensus (-26.6% surprise).
EPS surprise · last 4Q
0 of 1 beats
Estimate
Actual
Q3 26
-26.6%
Revenue trend · last 8Q
—
—
—
—
—
—
—
—
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
Q2 26
$0
$0
$0
$0
$0
$0
$0
$0
Margins · last 8Q
No margin history available.
Wall Street consensus
3 analysts · 100% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
100%
Hold
0%
Sell
0%
Median Price Target
—
Latest: Goldman Sachs · Jul 21, 2026
vs Industry
How ELVN stacks vs Biotechnology
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.
Related